Global Markets

COVID cull: Valneva cutting workforce and manufacturing ops

The discontinuation of its COVID program has led Valneva to resize its operations and question the use of its Livingston, UK facility. French vaccine firm Valneva SE developed VLA2001, an inactivated COVID-19 vaccine candidate, approved in the European Union (EU) in January 2022. Despite initial orders to supply up to 100 million doses in the UK, and a further 60 million doses in Europe last year, the changing COVID-19 pandemic landscape meant Valneva’s vaccine never achieved the rollout seen with…

Neurophth enters $140m gene therapy collaboration with Cyagen

Wuhan Neurophth has announced a $140 million agreement to use Cyagen’s AI platform to discover novel AAV vectors. Cyagen is a Santa Clara, California gene therapy contract research organization (CRO) with offices in China and Japan that offers genetically modified rodent models. Neurophth is developing gene therapies for ophthalmology indications. The company’s lead drug recently started a Phase III trial for ND4-mediated Leber’s hereditary optic neuropathy (ND4-LHON) with plans to conduct trials of the drug in China and the US.…

ten23 looks to on-body-injectors to reduce healthcare costs

CDMO ten23 health is supporting customers to develop an on-body-injector platform, which it says could lower overall treatment costs. Ten23, a contract development manufacturing organization (CDMO) focused on developing and commercializing injectable biopharmaceuticals met BioProcess Insider at CPHI, Frankfurt to discuss its on-body-injector activity. “Instead of holding and keeping in position a syringe for the time of injection, on-body-injectors are stuck to the body,” explained Michael Petersen, ten23’s chief commercial officer. “A button is pressed, and a small motor is…

JW partners with 2seventy to develop T Cell immunotherapies

Shanghai JW Therapeutics will partner with Boston’s 2seventy bio to use 2seventy’s cell therapy platform to develop T cell-based immunotherapies for Greater China. The collaboration will focus initially on 2seventy bio’s MAGE-A4 TCR program in solid tumors. JW will be responsible for development, manufacturing, and commercialization within China. 2seventy bio will receive milestones and royalty payments on revenues in China, and 2seventy may use JW’s clinical data to support ex-China development. Financial details of the agreement were not disclosed. JW…

Catalent cuts full year forecast citing COVID, currencies and costs

Catalent has cut its 2023 forecast after lower COVID-19 related product demand, inflation and currency headwinds impacted Q1 biologics revenue. The contract development manufacturing organization (CDMO) reported revenue for the three months ended September 30 of $1.02 billion, roughly the same as it was in the comparable period in 2021. Meanwhile, net income fell 52% to $61 million. The contribution from Catalent’s biologics business – which includes large molecule drug development and manufacturing as well as cell and gene therapies…

Gradual capacity rollouts reducing lead times, says Thermo

Bioproduction capital expenditure projects totaling upwards of $600 million are coming online and bringing lead times back to a pre-pandemic level, says Thermo Fisher. In March 2021, Thermo Fisher Scientific announced plans to invest “more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022.” This included a range of capacity expansion projects focused on single-use technologies, chromatography resins, and cell culture media already in the company’s pipeline either already underway or expedited due to COVID-19-related…

CMO initial offering: Adding an ‘R’ or ‘T’ blurs message, says marketing expert

The ‘D’ for ‘Development’ has become standard among the nomenclature of contract manufacturing organizations (CMOs) but the addition of an ‘R’ for ‘Research’ or ‘T’ for ‘Testing’ is needless and confusing, says marketing specialist Raman Sehgal. It sounds like the start of a joke, but what do you call a collection of biopharma manufacturing service firms? ‘Suppliers’ is too vague; ‘Third-party manufacturers’ is too clunky; CRAMS (Contract Research and Manufacturing Services), meanwhile, has not been used outside of Asia since…

VectorBuilder raises $57m in China for gene therapy delivery

Chicago-based VectorBuilder, a gene therapy delivery CDMO, raised $57 million in a Series C round from China investors. VectorBuilder develops and optimizes gene delivery products for research institutions and pharma companies. Earlier this year, the contract development and manufacturing organization (CDMO) announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou, China. The C round was co-led by Legend Capital, Suikai Investment (55% owned by state-owned firm Guangzhou Development District Investment Group) and Yuexiu Industrial…

J&J and Roche feeling the biosimilar bite in Q3

Both Johnson & Johnson and Roche are feeling pressure from biosimilars as sales of blockbuster products such as Remicade (infliximab) and Lucentis (ranibizumab) drop in Q3. J&J’s immunosuppressive monoclonal antibody Remicade has seen biosimilar competition in the US since 2016 when Pfizer’s Inflectra won approval. But while a series of pricing measures and a lack of challenge from interchangeable products have kept J&J from seeing a total sales wipe-out, the firm continues to see its infliximab revenues erode. For the…

BioPlan report: Buoyant bioprocess space will continue to shine post-COVID

Automation, innovation, and process optimization are driving higher yields, lower costs, and multiple capacity options for biomanufacturers, says BioPlan Associate’s Eric Langer. Ahead of the trade show on November 1-3, BioPlan Associates produced an article for the CPHI Frankfurt Annual Report, presenting a detailed analysis of the findings from its Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production and predicting key trends for the future of biomanufacturing. The key takeaways are: Industry growth: Over the past 10 years…